Skip to content

Speakers

Expand/Collapse

Andrea Crotti
Principal Scientist
Astellas

Day One

Thursday 13th December 2018

4:00 pm | The Role of Microglial BIN1 in Alzheimer’s Disease: From Genetics to Target Validation

Anindya Bhattacharya
Scientific Director
Janssen

Day Two

Thursday 13th December 2018

3:45 pm | Discovery to Clinical Evaluation of Neuroinflammation: The Microglial P2X7-NLRP3 Axis

Christian Haass
Professor, Laboratory of Neurodegenerative Disease
University of Munich

Day Two

Thursday 13th December 2018

10:45 am | TREM2, from Basic Functions to a Therapeutic Target

David Hansen
Scientist
Genentech

Day One

Thursday 13th December 2018

8:45 am | Microglia: Suppress or Promote?

Dimitry Ofengeim
Neuroinflammation-Lab Head
Sanofi

Day One

Thursday 13th December 2018

8:15 am | The Interface of Inflammation & Cell Death: Disease Progression in Multiple Sclerosis & Beyond

Eduard Urich
Principle Scientist
Roche

Jamie Bilsland
Chief Scientific Officer
AstronauTx

Day One

Thursday 13th December 2018

2:30 pm | Moving Away from Microglial Targets & Appreciating Astrocyte Contribution

Jane Osbourn
Chief Scientific Officer
Alchemab

Day Two

Thursday 13th December 2018

1:45 pm | Panel Discussion: Investing in Neuroinflammatory Targets & Backing Smaller Companies Research

Johan Luthman
Executive Vice President, Research & Development
Lundbeck

Day One

Thursday 13th December 2018

11:30 am | From Animal to Man: Building Target Engagement to Proof of Concept Pathway

Jonathan Behr
Partner
Dementia Discovery Fund

Day Two

Thursday 13th December 2018

1:45 pm | Panel Discussion: Investing in Neuroinflammatory Targets & Backing Smaller Companies Research

Karel Otero-Gutierrez
Principal Scientist
Eisai

Day Two

Thursday 13th December 2018

9:15 am | Audience Discussion: Working with the Right Cells In Vitro

Karpagam Shalu Srinivasan
Senior Scientist
Alector

Day One

Thursday 13th December 2018

12:00 pm | Stabbing in the Dark: Biomarkers of Microglial Pathway Activation

Malu Tansey
Director, Center for Translational Research in Neurodegenerative Disease & the Parkinson’s Foundation Research Center
The University of Florida College of Medicine

Day One

Thursday 13th December 2018

4:30 pm | Panel Discussion: Are We Chasing the Wrong Phenomenon?

Day Two

Thursday 13th December 2018

11:15 am | The Role of Innate Immune Dysfunction & Chronic Inflammatory Disease in Neurodegeneration

Maria Carrillo
Chief Science Officer
Alzheimer’s Association

Day Two

Thursday 13th December 2018

1:15 pm | Beyond the Usual Suspects: Promoting Novel Thinking

Matt Blurton-Jones
Associate Professor, Department of Neurobiology & Behavior
University of California, Irvine

Day Two

Thursday 13th December 2018

8:15 am | Using iPS-Microglia & Chimeric Models to Examine the Neuroimmunology of Alzheimer's Disease

Matthew Fell
Principal Scientist, Neuroimmunology
Merck Research Laboratories

Day One

Thursday 13th December 2018

12:30 pm | The Challenge of Developing Translatable Biomarkers to Guide the Clinical Interrogation of LRRK2 Kinase Inhibitors for Parkinson’s Disease

Rebecca Mathew
Senior Scientist, GpGx-Genome Sciences
Merck Research Laboratories

Day One

Thursday 13th December 2018

2:00 pm | Single Cell Sequencing & Spatial Transcriptomic Approaches to Characterize Human Cells & Tissues

Richard Ransohoff
Venture Partner
Third Rock Ventures

Day One

Thursday 13th December 2018

4:30 pm | Panel Discussion: Are We Chasing the Wrong Phenomenon?

RJ Tesi
Chief Executive Officer & Chief Medical Officer
INmune Bio

Day Two

Thursday 13th December 2018

4:45 pm | Panel Discussion: Optimizing Clinical Trial Study Design & Finding the Appropriate Controls for Patients

2:15 pm | Recipe for Success: Design Neuro Trials to Look Like Oncology Trials!

Robert Paul
Chief Medical Officer
Alector

Day Two

Thursday 13th December 2018

4:45 pm | Panel Discussion: Optimizing Clinical Trial Study Design & Finding the Appropriate Controls for Patients

4:15 pm | Reviewing Early Biomarker Read Outs to Improve Drug Development

Sue Bruhn
Chief Executive Officer & President
Tiaki Therapeutics

Day Two

Thursday 13th December 2018

8:45 am | Development of Targets Identified from Patients & Validated With Ex Vivo & In Vivo Models of Neuroinflammation